Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
MDWD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.78 - $24.00
Previous CloseN/A
Volume29.05K
Average Volume (3M)81.26K
Market Cap
$174.63M
Enterprise Value$151.46M
Total Cash (Recent Filing)-$337.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 28, 2025EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.07
Shares Outstanding11,251,766
10 Day Avg. Volume104,610
30 Day Avg. Volume81,264
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.80
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit57.50
Enterprise Value/Ebitda-5.42
Forecast
1Y Price Target
$30.00Price Target Upside86.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Mediwound News
PremiumCompany Announcements
MediWound’s Earnings Call: Progress Amid Financial Challenges
PremiumCompany Announcements
MediWound Reports 2024 Financials and Strategic Advances---
Bulls Say, Bears Say
Bulls Say
Market OpportunityEscharEx is being developed for enzymatic debridement of chronic wounds in the outpatient setting, representing a potential ~$2.5B market opportunity.
Product ValidationMediwound has secured an additional collaboration for its DFU study, with Kerecis joining to contribute its MariGen Fish-Skin graft, representing additional validation for the potential of EscharEx.
Regulatory SupportNew Medicare policy could strengthen EscharEx adoption by emphasizing the need for complete wound debridement before applying cellular and/or tissue-based products.
Bears Say
Approval DelaysNexoBrid guidance tightened towards lower end, reflecting adjusted timelines for EU approval of the manufacturing facility.
Capacity ConstraintsGlobal demand for NexoBrid currently exceeds MDWD's manufacturing capacity by roughly threefold, a dynamic that will ease over the course of this year as manufacturing capacity ramps.
Production LimitationsNexoBrid sales are limited only by supply, as demand for the product continues to exceed supply.
---
Ownership Overview
―
Insiders
1.87% Mutual Funds
28.39% Other Institutional Investors
65.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
MDWD FAQ
What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $12.78 and its highest was $24.00 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $174.63M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s upcoming earnings report date is May 28, 2025 which is in 56 days.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Mar 19, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.576 by $0.216.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.65.
How many shares outstanding does Mediwound have?
Mediwound has 11,251,766 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.576. Following the earnings report the stock price went down -5.138%.
Which hedge fund is a major shareholder of Mediwound?
Currently, no hedge funds are holding shares in MDWD
---
Mediwound Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (86.68% Upside)
$30.00 (86.68% Upside)
Blogger Sentiment
Bullish
MDWD Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 252.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 5.8%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.40%
12-Months-Change
Fundamentals
Return on Equity
-96.33%
Trailing 12-Months
Asset Growth
10.59%
Trailing 12-Months
Company Description
Mediwound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
---
MDWD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant clinical and commercial progress, particularly with EscharEx and NexoBrid, along with strategic collaborations and a strong financial backing. However, the increased operating and net losses, along with a decline in gross margin, suggest financial challenges. The positive advancements in products and strategic partnerships indicate a promising outlook despite these financial hurdles.Read More>---
MDWD Stock 12 Month Forecast
Average Price Target
$30.00
▲(86.68% Upside)
Technical Analysis
Best Analysts Covering MDWD
1 Year
1 Year Success Rate
10/18 ratings generated profit
1 Year Average Return
+33.46%
reiterated a buy rating 13 days ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +33.46% per trade.
---